Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at [phone].

The Allegations: Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate

According to the complaint, one of Corcept's lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). During the class period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the class period, Defendants repeatedly told investors that “relacorilant is approaching approval.”

Plaintiff alleges that in truth, the FDA had raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result there was a known material risk that Corcept's relacorilant NDA would not be approved.

The complaint continues that on December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025, or 50.4%.

What Now: You may be eligible to participate in the class action against Corcept Therapeutics Incorporated. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.